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Background: Although glargine and detemir are both FDA-approved in the U.S. as long-acting insulin analogues,
inherent differences in the insulins may lead to varying outcomes. This study examined changes in clinical measures and
associated costs for veterans with type 2 diabetes on insulin therapy converted from insulin glargine to insulin detemir.
Methods: A retrospective before-and-after comparison study was performed at a single-site medical center located in the
southwestern U.S., comprising 133 Veterans diagnosed with type 2 diabetes receiving insulin therapy with glargine and
converted to insulin detemir using a 1:1 unit dosage ratio. Patients’ A1c, weight, body mass index, total daily dose, and
estimated monthly insulin costs during and after conversion were compared employing Wilcoxon signed-rank tests. These
measures were similarly assessed in patients at A1c goal (<7 %) prior to conversion.
Results: When switched from insulin glargine to insulin detemir, an increase in A1c (median of 7.7 % to 8.3 %, p < 0.01)
and total daily dose (TDD: 40 to 46 units/day, p < 0.01) resulted. Monthly insulin costs decreased 19 % ($47 to $38,
p < 0.01), or roughly a one-year savings of $110 per patient. An increase in A1c was similarly observed for patients
at-goal prior to conversion but remained at-goal post-conversion (6.5 % to 6.7 %, p = 0.02).
Conclusion: The increase in A1c and TDD following conversion from insulin glargine to insulin detemir suggests that
glargine requires a smaller amount of units to reach the same glycemic-lowering ability compared to detemir. Despite
the observed insulin cost savings associated with detemir, future studies should also determine overall costs (including
indirect) and benefits associated with switching from glargine to detemir among Veteran with Type 2 diabetes.
Keywords: Detemir, Glargine, Glycemic control, Long-acting insulin, Type 2 diabetes, VeteransIntroduction
In 2011, diabetes mellitus was reported to have a preva-
lence rate of 8.3 % in the U.S., affecting approximately
25.8 million Americans [1]. As major risk factors for
diabetes, such as obesity, are becoming more common in
the population, the prevalence of diabetes in adults has
risen significantly from 1.9 million in 1958 to 18.8 million
in 2010 [1–3]. The majority of these adults have type 2
diabetes (90-95 %) [1]. For the U.S. veteran population* Correspondence: estock@sw.org
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the prevalence of diabetes is much greater. Given that
approximately 20 % of this population has diabetes, there
is a growing concern over the expected increase in
healthcare costs associated with the rising prevalence of
diabetes [1, 4].
It is estimated that individuals with diabetes have more
than double the medical costs of those without diabetes
[1]. This increase in costs is largely contributable to the
continuous treatment of these patients, as well as the
treatment of serious complications arising from diabetes,
including retinopathy, nephropathy, neuropathy, and
foot infections that may potentially lead to amputations.
While direct medical costs associated with the treatment
of diabetes in the U.S. during 2002 were estimated atcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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ivity due to disability and mortality were estimated to
be an additional $40 billion, totaling to $132 billion [5].
In 2007, the total estimated costs of diabetes rose to
$174 billion, including $116 billion in direct medical
costs and $58 billion from reduced productivity [6].
These estimates are overwhelming and highlight the
need for greater diabetes management to improve
patients’ clinical outcomes while also lowering their
accrued medical costs.
Initial management of type 2 diabetes commonly en-
tails the use of oral anti-hyperglycemics in the biguanide
and sulfonylurea class. However, normal progression of
the disease often leads to the need for insulin therapy
for glycemic control and prevention of diabetes compli-
cations. Approximately 26 % of adults diagnosed with
diabetes receive insulin therapy [1]. The use of insulin
for the treatment of diabetes can have a significant
impact on patients’ quality of life, as well as generate
additional costs to the health care system by providing
additional supplies and equipment needed for safe and
effective insulin therapy management. Given the high
cost associated with the management of diabetes each
year and the longevity of treatment after diagnosis, these
annual costs accumulated over time have immense im-
plications for the patients themselves and the healthcare
systems providing care for these patients. Long-acting
insulin plays a major function in the management of
diabetes due to its role in basal blood glucose control.
Such agents are designed to mimic the natural physio-
logic effects of insulin within the human body without a
defined peak in activity, thereby decreasing the risk of a
hypoglycemia-related side effect. Insulin glargine and in-
sulin detemir are currently the only FDA-approved long-
acting insulin analogues available in the U.S. In clinical
trials, the efficacy of insulin detemir has been shown to
be equivalent to that of insulin glargine with its package
labeling suggesting a 1:1 unit conversion between the
two agents [7].
However, despite both glargine and detemir being classi-
fied as long-acting insulin analogues with similar efficacy,
numerous studies have found substantial differences in
clinical outcomes between the anti-hyperglycemic agents.
For example, in several studies, insulin therapy with
detemir resulted in less weight gain and a lower rate of
hypoglycemia compared to therapy with glargine among
patients with type 2 diabetes [8–13], suggesting that
detemir may not be as potent as glargine. Isoglycemic
clamp studies have shown similar duration of action be-
tween the long-acting agents at about 24 h [14]; however,
the results of insulin detemir’s phase III clinical trials have
shown that the two insulins vary in their duration of ac-
tion [7]. Whereas insulin glargine typically has a duration
of action lasting 24 h or longer, the duration of action forinsulin detemir has been shown to be dose-dependent,
ranging from 6 to 24 h [7, 15]. These differences may
further lead to disparities in clinical outcomes for patients
with type 2 diabetes prescribed either one of these insulin
agents.
A recent study of 973 insulin-naïve patients initiated
on either insulin glargine or insulin detemir for basal
blood glucose control compared changes in A1c, the
percent of patients reaching A1c goal of under 7 %, and
the insulin dose required [8]. This 24-week, randomized,
treat-to-target study found no difference between the in-
sulins in A1c reduction or in the proportion of patients
reaching A1c goal. However, patients receiving therapy
with detemir required a significantly greater dose of insu-
lin to achieve similar results. Patients receiving detemir
were initiated on twice daily dosing, which has been asso-
ciated with an increase in insulin dose without corre-
sponding improvement in glycemic control [9]. Another
randomized, treat-to-target study evaluated similar out-
comes but initiated both treatment groups with once daily
dosing [9]. A second dose was added to the insulin dete-
mir group only if the pre-dinner plasma glucose levels
were elevated. Similar findings were observed with no sig-
nificant difference in ending A1c between the groups.
However, the mean total daily dose (TDD) was lower with
the use of insulin glargine.
Although clinical trials provide a well-controlled envir-
onment to compare outcomes associated insulin glargine
versus insulin detemir, the stringent insulin titration
protocol that is applied makes the data difficult to
generalize to everyday practice. Therefore, this study
aimed to examine the clinical and cost effectiveness of
these insulin analogues in the context of a real-world
scenario. Specifically, we assessed changes in patients’
clinical measures and medication costs associated with
the conversion from insulin glargine to insulin detemir
for basal blood glucose control among veterans seeking
care in the VA diagnosed with type 2 diabetes. The switch
from insulin glargine to detemir was due to a change in
the preferred basal insulin for the institution’s formulary.
Methods
To compare clinical and financial outcomes associated with
switching from insulin glargine to insulin detemir in a vet-
eran population with type 2 diabetes, a retrospective before-
and-after study design was performed in a large integrated
veteran healthcare system located in southwestern U.S. The
study was approved by the local institutional review board
(Central Texas Veterans Health Care System IRB) prior to
study initiation. A ProClarity search of the VA National
Data Cube identified 365 patients with an active prescrip-
tion for both insulin detemir and insulin glargine between
June 2010 and June 2011. Inclusion criteria restricted study
subjects to include male veterans aged 18 to 89 years with a
Table 1 Patient demographics with at conversion and
post-conversion clinical measures (N = 133)
Patient characteristics Frequency (%)
Age (years) Mean (SD): 66.3 (9.7)





Insulin Glargine (At Conversion)
At A1c Goal (<7 %) 24 (18.1)
Pre-Meal Bolus Insulin 72 (54.1)
Oral Anti-hyperglycemics 78 (58.7)
Both Bolus and Oral 29 (21.8)
Insulin Detemir (Post-Conversion)
At A1c Goal (<7 %) 21 (15.8)
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treatment for a duration of at least 6 months prior to
switching to insulin detemir, and a length of insulin
detemir therapy for at least 6 months post-conversion.
Only patients with valid clinical outcome measures col-
lected from chart records at the time of insulin switch
and post-conversion were included, reducing the study
sample to 133 patients.
Measures
Demographic measures included age and race (white,
black, and other/unknown). Clinical outcome measures
were assessed at the time of conversion from insulin
glargine to insulin detemir (at conversion) and post-
conversion (insulin therapy with detemir). Patients’ post-
conversion A1c was measured at least 90 days but no
more than nine months after the beginning of therapy
with insulin detemir. Patients’ total daily dose (TDD, in
units/day and units/kg/day), weight (kg), and body mass
index (BMI, in kg/m2) were obtained at conversion and
six months post-conversion. Patients with an A1c at goal
(less than 7 %) during the insulin switch and post-
conversion were documented. Oral anti-diabetic agent
and pre-meal bolus short-acting insulin use at conver-
sion was also documented. Monthly insulin costs were
estimated by calculating the number of vials required to
fill a 30-day supply of the insulin using TDD and the
average cost per vial at the time from which dose was
collected based on the local VA pharmacy invoices.
Data analysis
Means and frequencies were calculated for patient charac-
teristics and clinical and financial outcomes at conversion
(insulin glargine) and post-conversion (insulin detemir).
Analyses employing Wilcoxon signed-rank tests were per-
formed comparing patients’ A1c, weight, BMI, and TDD,
as well as estimated monthly insulin costs during and after
conversion. Similar analyses were performed for patients
reaching A1c goal (<7 %) prior to conversion while on in-
sulin glargine therapy to determine if results varied.
McNemar’s test was used to test marginal homogeneity
for the proportion of patients observed to have at-goal
(<7 %) A1c at conversion and post-conversion. Correla-
tions between the change in A1c and both the use of oral
anti-diabetic agents and pre-meal bolus short-acting insu-
lin were assessed using Spearman’s rank correlation coeffi-
cient. All analyses were performed using SAS, Version 9.2
(Cary, NC), assuming a type I error of α = 0.05.
Results
Among 133 male veterans switching from insulin glargine
to insulin detemir, patients were predominantly older with
a mean age of 66 years (SD = 10) and white (74 %; Table 1).
The proportion of patients at A1c goal decreased from18 % with insulin glargine to 16 % with insulin detemir.
The proportion of veterans on pre-meal bolus short-
acting insulin and oral anti-hyperglycemic agents at the
time of conversion was 54 % and 59 %, respectively, with
22 % on both bolus and oral medication.
Following insulin conversion, patients’ A1c increased
significantly from a median of 7.7 % with insulin glargine
to 8.3 % with insulin detemir (p < 0.01; Table 2). This in-
crease in A1c was observed among 61 % of patients.
Similarly, the median TDD rose from 40 to 46 units/day
(p < 0.01). Switching to insulin detemir therapy was asso-
ciated with a change in patients’ weight with nearly two-
thirds (64 %) of patients experiencing weight loss. The
majority of patients (63 %) also experienced a drop in
BMI (median of 31.7 to 31.5 kg/m2, p < 0.01). A decrease
in patients’ estimated monthly insulin costs was observed
during post-conversion with insulin detemir (median of
$38 vs. $47, p < 0.01). That is, while TDD increased,
monthly estimated insulin costs decreased 19 %. This
amounts to approximately $110 per patient annually, or
$11,000/year for every 100 patients. A decrease in insulin
costs was observed for 74 % of the sample.
Although a significant increase in A1c was observed dur-
ing post-conversion with insulin detemir, no difference in
the proportion of patients at A1c goal at conversion versus
post-conversion was observed (p = 0.47 per McNemar’s
test). A weak but significant positive correlation was found
between changes in A1c measurements from at conversion
to post-conversion with the use of pre-meal bolus insulin
(r = 0.17, p < 0.05). Bolus insulin use appeared to be associ-
ated with an increase in patients’ A1c during insulin ther-
apy with detemir. Alternatively, the correlation between
oral anti-diabetic agents and change in A1c revealed a near
independent relationship (p = 0.02, p = 0.81). For patients
Table 2 Clinical and cost measures for insulin glargine at conversion versus insulin detemir post-conversion (N = 133)
Measures Glargine Detemir p-value* Frequency of trend
post-conversion (%)aMean (SD) Mean (SD)
Median (Min-Max) Median (Min-Max)
A1c (%) 8.0 (1.4) 8.5 (1.8) <0.01 81 (60.9) ↑
7.7 (5.3-13.6) 8.3 (5.3-14.7)
A1c (mmol/mol) 64 (8) 69 (4) <0.01 81 (60.9) ↑
61 (34–125) 67 (34–137)
Weight (kg) 109.7 (38.9) 109.0 (37.1) <0.01 85 (63.9) ↓
100.0 (66.2-351.0) 100.7 (69.4-323.0)
BMI (kg/m2) 32.7 (6.4) 32.3 (5.9) <0.01 84 (63.2) ↓
31.7 (19.3-52.3) 31.5 (21.1-49.2)
TDD (units/day) 46.0 (29.8) 54.9 (33.6) <0.01 79 (59.4) ↑
40.0 (5.0-190.0) 46.0 (5.0-150.0)
TDD (units/kg/day) 0.42 (0.2) 0.50 (0.3) <0.01 79 (59.4) ↑
0.39 (0.04-1.24) 0.46 (0.04-1.36)
Estimated Cost ($) 44.24 (21.69) 40.41 (19.49) <0.01 99 (74.4) ↓
47.28 (21.43-141.80) 38.12 (19.06-95.30)
*Wilcoxon signed-rank test
aColumn represents number and percent of patients with particular trend for post-conversion, either increase (↑) or decrease (↓)
Table 3 Clinical and cost measures for insulin glargine at
conversion versus insulin detemir post-conversion for those
observed at A1c goal (<7 %) while on insulin glargine (N = 24)
Measures Glargine Detemir p-value*
Mean (SD) Mean (SD)
Median (Min-Max) Median (Min-Max)
A1c (%) 6.3 (0.5) 7.1 (1.9) 0.02
6.5 (5.3-6.9) 6.7 (5.3-14.5)
A1c (mmol/mol) 45 (18) 54 (3) 0.02
48 (34–52) 50 (34–135)
Weight (kg) 104.9 (25.8) 104.0 (24.2) 0.27
98.5 (68.2-169.4) 96.8 (73.1-169.9)
BMI (kg/m2) 31.9 (6.7) 31.6 (6.0) 0.16
30.0 (19.3-46.3) 29.7 (23.4-44.6)
TDD (units/day) 36.6 (24.6) 49.4 (36.8) 0.05
33.5(5.0-100.0) 36.0 (5.0-140.0)
TDD (units/kg/day) 0.34 (0.2) 0.39 (0.26) 0.07
0.33 (0.04-0.77) 0.31 (0.04-1.00)
Estimated Cost ($) 39.13 (16.83) 33.35 (16.13) 0.02
36.32 (23.64-70.92) 38.12 (19.06-76.12)
*Wilcoxon signed-rank test
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use (N = 24), an increase in A1c values from a median of
6.5 % with insulin glargine to 6.7 % with insulin detemir
was observed (p = 0.02; Table 3). Post-conversion, patients
tend to remain at goal.
Discussion
The results of this study reflect the outcomes of an older
male veteran population diagnosed with type 2 diabetes.
Although our sample size was relatively small, a signifi-
cant increase in A1c was observed after switching to in-
sulin detemir from insulin glargine. Since patients were
switched using a 1:1 unit conversion, the increase in A1c
suggests that insulin detemir and insulin glargine are not
equipotent. In fact, based on the estimates for total daily
dose between the groups, insulin glargine requires 16 %
less units than insulin detemir to achieve the same gly-
cemic control. Additionally, when examining patients
who had an at goal A1c prior to the conversion to dete-
mir, an increase in A1c was similarly observed post-
conversion, though still remained at goal. Recent litera-
ture has similarly shown an insulin detemir dose re-
quires a larger number of units compared to insulin
glargine in order to reach comparable A1c levels [8–11].
Concurring with previous studies, the majority of pa-
tients experienced a decrease in weight and BMI after
conversion from insulin glargine to insulin detemir. Our
findings were similar to that of a recent study by Bryant
and colleagues (2013), which examined 31 patients with
type 1 or type 2 diabetes who converted from insulin
glargine to insulin detemir after a Medicaid formularyswitch [16]. Among those with type 2 diabetes, the mean
basal insulin dose was higher with detemir (74 vs. 56
units/day, p < 0.01). This amounts to a requirement of
32 % higher doses of insulin detemir compared to insulin
glargine. Despite insulin dose titrations, no change in A1c
occurred from baseline to 12 months post-conversion,
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mir are not equipotent.
In our study, the presence of pre-prandial bolus insulin
and oral anti-hyperglycemics was evaluated since titration
of these agents may also affect A1c levels. The presence of
pre-prandial bolus insulin was weakly correlated with an
increase in A1c, which is contrary to what would be ex-
pected given that the bolus insulin may also be titrated to
contribute to improved glycemic control. A possible ex-
planation for this result is that the patients on pre-
prandial bolus insulin may have diabetes that is more diffi-
cult to control. The relationship between pre-meal bolus
insulin use and increased A1c should be evaluated in a lar-
ger sample. Oral anti-hyperglycemics and change in A1c
were found to be independent. This is likely due to the
fact that most patients have been titrated up to the max-
imum doses of oral anti-hyperglycemics prior to initiating
insulin, so titrations after the conversion were rare.
In a previous retrospective cohort analysis by Borah and
colleagues (2009), insulin glargine and insulin detemir
were associated with comparable mean adjusted all-cause
pharmacy costs, medical costs, and total health care costs.
However, insulin glargine was associated with significantly
higher diabetes-related medical costs and total diabetes-
related health care costs [17]. Cost estimation in this study
was solely based on medication costs, and despite the
increased number of units needed to achieve a similar
A1c goal, a 19 % monthly cost savings results from
switching insulins.
To our knowledge, this study is one of few that com-
pare clinical outcomes and medication costs for patients
with type 2 diabetes converted from insulin glargine to
insulin detemir indicated for basal blood glucose control
reflecting real-world results. In this study, the providers
do not adhere to a strict protocol (such as with clinical
trials), and practice may vary from provider to provider.
Per study design, patients were compared to themselves
to help control for possible confounders that may influ-
ence results. Additionally, the precise number of units
the patients were using was obtained from chart review
and used in the analyses. This strengthens our study as
many previous retrospective studies have used dispens-
ing histories to evaluate daily dose which may not be an
accurate estimate of insulin use as these records do not
account for discarded insulin [17, 18].
Limitations
Given the sample’s size and patient characteristics, find-
ings may be difficult to generalize to non-VA popula-
tions. Although this study reflects “real-world” results
of a conversion from insulin glargine to insulin detemir,
there are many confounders including change in diet,
exercise, and compliance that were unadjusted for and
may have affected results. Desirable future studieswould entail a larger sample size with an additional
group that would receive continued prescribing of insu-
lin glargine over the entire period of the study.
Though limited by this study’s sample size, further suba-
nalyses should compare outcomes across groups with
varying BMI. When examining the subgroup of patients
with A1c at-goal (<7 %, n = 24 patients) on glargine, the
change in weight and BMI was no longer significant, and
the effect of switching insulin on TDD and costs was less-
ened. From this, it appears that the inclusion of patients
with higher baseline A1c (not at-goal) while on insulin
glargine tend to initially have higher BMI, TDD, and costs.
In fact, a three-fold increase in median A1c after switching
insulin was observed after including patients with higher
A1c (+0.2 % at-goal vs. +0.6 % all patients). Similarly, me-
dian TDD was doubled (+2.5 units/day at-goal vs. +6.0
units/day all patients). And, interestingly a median de-
crease in costs was observed that was five times the in-
crease in costs observed for patients with A1c < 7 %
(+$2.18 at-goal vs. – $9.16 all patients).
Initially the conversion was done on a 1:1 basis with dose
titrations allowed after the conversion in order to maintain
or improve the patient’s hemoglobin A1c, as needed. This
led to different maximum TDD for each insulin. However,
we believe the effect is minimal given that the higher max-
imum was observed with glargine but the average and me-
dian TDD was greater with detemir. Doses exceeding 100
units/day were typically divided equally into twice daily.
Evaluating the number of patients who required an
increase in frequency of administration to twice a day
dosing after conversion would help determine the actual
clinical impact of the proposed dose-dependent differ-
ences in duration of action of insulin detemir. Finally,
the calculation of cost only included the cost of the insu-
lin. Other factors that may affect the cost savings seen in
this study are the cost of labor required to convert pa-
tients and the cost of the additional insulin syringes for
those patients who are eventually changed to twice daily
dosing after the conversion. Additionally, patient indir-
ect costs were not factored into this cost measure.
Conclusion
In an older, mainly white veteran population with type 2
diabetes, conversion from insulin glargine to insulin dete-
mir resulted in an increase in A1c post-conversion, de-
crease in weight and BMI, and an increase in total daily
dose. Therefore, the study suggests that insulin glargine
and insulin detemir are not equipotent. However, no
difference in the proportion of patients reaching A1c
goal was observed. A monthly cost savings was ob-
served for most patients switching to insulin detemir.
On average, switching to insulin detemir resulted in a
19 % reduction in costs, or per-patient savings of $110
annually on insulin expenditures.
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